Primal Supplements Group, working with the U.S. Food and Drug Administration, has issued a voluntary recall of its men's health supplement Primal Herbs Volume after testing revealed the product contained sildenafil, the prescription active ingredient found in Viagra.
The recall covers all orders placed between July 2 and September 19, 2025. The supplement was packaged in an 8½-ounce round container with a green label and was sold without listing sildenafil on its ingredients panel. Consumers who purchased the product are advised to stop using it immediately and can contact hello@primalherbs.com for a replacement or store credit.
What the Left Is Saying
Public health advocates and consumer safety groups are using the recall to call for stronger FDA oversight of the dietary supplement industry. These groups argue that the incident highlights gaps in supplement regulation, noting that products can reach consumers without adequate safety testing or ingredient disclosure. Consumer Watchdog and other organizations have long advocated for requiring FDA pre-approval of supplement ingredients, particularly those with pharmaceutical properties.
Democratic lawmakers have also pointed to this recall as evidence supporting the need for legislative reforms to the Dietary Supplement Health and Education Act of 1994. Senator Richard Blumenthal (D-CT) has previously introduced legislation to strengthen supplement safety requirements, arguing that current law leaves Americans vulnerable to undisclosed pharmaceutical ingredients in over-the-counter products.
What the Right Is Saying
Industry representatives and some conservative commentators say the recall demonstrates that the existing regulatory framework is working as intended. They note that Primal Supplements Group voluntarily coordinated with the FDA to issue the recall, arguing this shows the system catches problems without heavy-handed government intervention.
The Natural Products Association, which represents supplement manufacturers, has emphasized that the vast majority of supplement companies comply with the law and that bad actors are rare. Some industry supporters argue that additional regulations could limit consumer access to beneficial supplements and burden small businesses with compliance costs. They contend that voluntary recalls and market accountability are sufficient tools for addressing isolated incidents.
What the Numbers Show
Sildenafil is the active ingredient in Viagra, prescribed to treat erectile dysfunction in men. Under the brand name Revatio, sildenafil is also prescribed to treat pulmonary arterial hypertension, a type of high blood pressure occurring between the heart and lungs. The Mayo Clinic provides clinical guidance on both uses.
The FDA recall covers a specific product window from July 2 through September 19, 2025. The supplement was sold in an 8½-ounce round container with green labeling. Consumers can contact the company at hello@primalherbs.com for remediation.
The Bottom Line
This recall underscores ongoing questions about the adequacy of supplement industry oversight. While the FDA regulates dietary supplements under a different framework than prescription drugs, cases where undisclosed pharmaceutical ingredients appear in products raise public health concerns. Consumers purchasing men's health supplements should be aware that some products may contain active ingredients not disclosed on labels. The FDA maintains a public database of supplement recalls that consumers can consult. Primal Supplements Group's cooperation with federal regulators illustrates how the recall system functions when companies identify potential safety issues, though critics argue pre-market testing could prevent such products from reaching consumers in the first place.